Clinical trial
Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous…
NCT00493220 · Baxter Healthcare Corporation, Industry · Completed
Key facts
| NCT number | NCT00493220 |
|---|---|
| Title | Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration |
| Official title | INcreased Flow Utilizing Subcutaneously-Enabled Ceftriaxone (INFUSE-Ceftriaxone) Study: A Phase I Study Comparing the Safety and Pharmacokinetics of Ceftriaxone Administered Subcutaneously With and Without Human Recombinant Hyaluronidase (HYLENEX Recombinant) and Intravenously in Human Volunteers |
| Acronym | INFUSE-Cftrx |
| Lead sponsor | Baxter Healthcare Corporation, Industry |
| Collaborators | Halozyme Therapeutics Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | SC HYLENEX and Ceftriaxone, SC Placebo and Ceftriaxone, IV Ceftriaxone |
| Enrollment | 30 |
| Start date | Jun 1, 2007 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Jun 28, 2007 |
| Last update posted | Dec 2, 2011 |
At a glance
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: